Table of Contents Table of Contents
Previous Page  512 / 812 Next Page
Information
Show Menu
Previous Page 512 / 812 Next Page
Page Background

S508

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

and calcium are represented over depression and mania. Here we

introduce the case of a young patient who had a treatment resistant

depression. However, his symptoms have been cured by adjust-

ing the level of magnesium, which was idiopathically lower than

normal lower limit.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1482

EV498

Acute administration of reboxetine

reduces alcohol self-administration

but, after a subchronic treatment with

this drug, alcohol self-administration

is enhanced

F. Alen

1 , 2 ,

, T. Marban Castro

1

, A.J. Ballesta-Garcia

1

,

M. Anton Valades

1

, M.T. Ramirez-Lopez

1

, M. Vazquez

1

,

N. Blanco

1

, D. Ouco

1

, M. Jaimez-Alameda

1

, R. Gomez de Heras

1

,

A. Serrano

2

, M.A. Gorriti

2

, J. Suarez

2

, F. Rodriguez de Fonseca

1 , 2

1

Laboratorio de Medicina Regenerativa, Hospital Regional

Universitario Carlos Haya, Fundación IMABIS, Avenida Carlos Haya

82, Sótano, 29010 Málaga, Spain

2

Departamento de Psicobiología, Facultad de Psicología, Universidad

Complutense de Madrid, 28223 Madrid, Spain

Corresponding author.

Introduction

Comorbidity between alcoholism and depression

has long been acknowledged, and the possibility that similar brain

mechanisms, involving both serotonergic (5-HT) and noradrener-

gic systems (NE), underlie both pathologies has been suggested.

Thus, inhibitors of NE and 5HT uptake have been proposed for

the treatment of alcoholism, as they have shown to reduce alco-

hol intake in various animal models. However, most of the studies

mentioned were carried out acutely and there is a lack of knowl-

edge of the possible long-term effects. Clinical studies report an

overall low efficacy of antidepressant treatment on alcohol con-

sumption, or even a worsened prognosis. In addition, several cases

of alcohol dependence following antidepressant treatment have

been reported in the literature.

Objectives

We aimed at comparing the acute and chronic effects

of the treatment with the antidepressant drug reboxetine on alco-

hol consumption.

Methods

We used a rat model of alcohol self-administration, and

two different schedules of reboxetine administration (acute and

chronic).

Results

Our results confirm the acute suppressant effects of

reboxetine on alcohol consumption but indicate that, when this

drug is administered chronically in a period of abstinence from

alcohol, it can significantly increase the rate of alcohol self-

administration.

Conclusions

These results are important for the understanding

of the clinical reports describing cases of increased alcohol con-

sumption after antidepressant treatment, and suggest that much

more research is needed to fully understand the long term effects

of antidepressants, which remain the most widely prescribed class

of drugs.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1483

EV499

Relationship between drug dreams,

affect, mood disorders and lucid

awakening in psychotic patients on a

treatment

D.F. Frías Ortiz

1 ,

, J.M. León Alegria

2

, Z. Fernández Guerra

3

,

O.W.M. Ali Al Shaban Rodriguez

4

, J.J. Fernández Miranda

5

,

A. Gonzalez Fernández

6

1

S.E.S.P.A- V Area- Mental Health of Asturias “Hospital de Cabue˜nes”,

Psychiatry and Mental Health, Gijón, Spain

2

S.M. “Salud Madrid“- S.G.A.P. 8, Psychiatry and Mental Health,

Madrid, Spain

3

SM Salud Madrid “Hospital Gregorio Mara˜non”, Psychiatry and

Mental Health, Madrid, Spain

4

S.E.S.P.A- VII Areaof Mental Health of Asturias “Hospital Alvarez

Buylla”, Psychiatry and Mental Health, Mieres, Spain

5

S.E.S.P.A- V Area-Mental Health of Asturias “CTI MONTEVIL-Hospital

de Cabue˜nes“, Psychiatry and Mental Health, Gijón, Spain

6

S.E.S.P.A. III Area Mental Health Asturias “Hospital de San Agustín”,

Psychiatry and Mental Health, Aviles, Spain

Corresponding author.

Introduction

This experimental trial aims to describe the expe-

riences felt by a group of patients diagnosed with different

psychotic disorders (schizophrenia, delusional chronic disorder,

etc.) inwhich the use of Benzodiazepine derivatives were related to

emergence of lucid dreaming and dissociative events (to see oneself

out of your one body, etc.), and to a lesser extent had subsequent

depressive symptoms. Fifty-six patientsweremonitored and linked

to the emergence of depressive symptoms related to the use of Ben-

zodiazepines or sedative-hypnotic. While on this treatment, they

had vivid or lucid dreaming.

Aims-objectives

To explore the relationship between occurrence

of drug dreams (DDs) and daytime negative affect with lucid awak-

ening during the course of a 9-week treatment.

Methods

Using the dream journal methodology, 56 participants

reported occurrence of dreams, dreamcontent, and ratings of affect.

The relationships between the experience of DD, dream content

(“active” vs “passive”), and affect were analysed usingmixedmodel

methods.

Results

The experience of DD was associated with higher levels

of negative affect (

P

< 0.001). The occurrence of DD did not decrease

significantly over the 9 weeks of the study. Benzodiazepine users

reported a higher occurrence of Lucid Awakening (

P

< 0.05) than the

other drug groups (zolpidem and clometiazol).

Conclusions

These results are consistent with the hypothesis that

DD can act as drug-conditioned stimuli to elevate negative affect.

Although correlational, such findings support the implementation

of psychological and pharmacological interventions aimed at min-

imizing the impact of DD on patients with lucid awakening and

psychosis.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1484

EV500

The sunshine induced placebo effect

in major depressive disorder patients

exhibits gender differences

J. Gailledreau

1 ,

, B. Gailledreau

1

, P. Desbonnet

2

,

P. Khalifa Soussan

3 , N.

Desbonnet

2 , S. B

ecque

1

1

Private CIC Ambroise-Paré, Psychiatry, Elancourt, France

2

Résidence Saint-Michel, Psychiatry, Gailledreau, France

3

GICIPI, Psychiatry, Toulouse, France

Corresponding author.

Rationale

Sunshine increases placebo effect in major depressive

disorder (MDD) patients (Gailledreau et al., 2015). Kokras et al.